top of page

Check your portfolio 24x7

Infinity Finserv (P) Ltd , An AMFI Registered Mutual Fund Distributor

Anuradha Mishra

US Biosecure Act: A Game Changer for Indian Pharma?


The US House of Representatives has taken a significant step by passing the BIOSECURE Act, which restricts drug companies from collaborating with specific Chinese biotechs over the next eight years. With a decisive 306-81 vote, this development is expected to reshape global pharmaceutical sourcing strategies. For Indian pharmaceutical players, the act opens doors to new opportunities, but challenges remain.


What Is the BIOSECURE Act?

The BIOSECURE Act aims to reduce reliance on Chinese pharmaceutical suppliers by preventing US government contracts and grants from being awarded to select Chinese firms. Notable companies like BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec, and WuXi Biologics are explicitly named in the bill. While the legislation still awaits Senate approval, its implications are already sending ripples through the global pharma industry.

Spotlight on Indian Pharma Companies:

As the US moves to diversify its pharmaceutical supply chain, Indian firms like Laurus Labs, Syngene International, Piramal Pharma, and Neuland Laboratories are poised to benefit. These companies are increasingly engaging with US-based clients, positioning themselves as viable alternatives to Chinese suppliers.

  • Laurus Labs:

    Laurus Labs sees this shift as a long-term opportunity. While initial projects are likely to be small-scale, the company is optimistic about gradual growth as US firms explore Indian alternatives.

  • Piramal Pharma:

    Piramal Pharma reports a surge in exploratory discussions, including inquiries, audits, and requests for proposals. However, major contracts are yet to materialize as clients remain in the evaluation phase.

  • Neuland Laboratories:

    Primarily focused on APIs (Active Pharmaceutical Ingredients), Neuland Labs has seen increased customer visits and discussions. However, the company notes that its niche differs from biologics-focused CDMOs (Contract Development and Manufacturing Organizations).

  • Syngene International:

    Syngene appears to be gaining traction, thanks to its established contracts with multinational corporations. CEO Jonathan Hunt highlighted a "material shift" in sourcing strategies among Big Pharma to mitigate risks. The company has seen a 50% year-over-year increase in Request for Proposals (RFPs) during its best-performing quarter in four years.


Market Reactions:

Shares of key Indian pharma companies reflect the growing optimism:

  • Laurus Labs: Up 3.5% at ₹508.

  • Neuland Labs: Down 1.7% at ₹12,430, though the stock has already rallied 135% in 2024.

  • Syngene International: Up 1.5% at ₹907.

  • Piramal Pharma: Up 3.5% at ₹224.5.


Opportunities and Challenges:

  • Opportunities

    The BIOSECURE Act is a wake-up call for the global pharmaceutical industry to reduce its dependence on Chinese suppliers. Indian pharma companies, with their $4 billion in API exports, are now seen as crucial players. While China dominates with $40 billion in API exports, even a modest shift of 20-30% could significantly boost India's market share.

  • Challenges

    Experts caution that Indian firms still lag behind global peers in areas like technology, trust, experience, and capacity for large-molecule biologics. Competing with well-established US and European firms will require substantial investments in infrastructure and innovation.


A Strategic Shift in Global Sourcing:

Aditya Khemka of InCred Healthcare PMS highlights the rationale behind the BIOSECURE Act:

"The West has grown wary of relying too heavily on China for raw materials, especially after witnessing instances like Russia weaponizing gas and China weaponizing the COVID vaccine. Diversifying supply chains is no longer optional—it’s essential."

The focus on reducing dependency on China aligns with broader geopolitical shifts. For Indian pharma companies, this is a golden opportunity to emerge as reliable alternatives.

Conclusion:

While the BIOSECURE Act holds immense potential for Indian pharma, success will depend on how quickly and effectively companies can scale their capabilities to meet global tandards. As the act progresses to the Senate, Indian firms must prepare for a competitive yet promising future. This pivotal moment could redefine India’s role in the global pharmaceutical landscape. Are Indian companies ready to seize the opportunity? Time will tell.

Disclaimer: The content is intended for informational purposes only and does not constitute investment advice or a recommendation to invest in any specific stock or company. The mention of stock names in this article is purely for contextual purposes related to the topic discussed. Readers are advised to conduct their own research or consult a financial advisor before making any investment decisions.

Soruce: ET Money & CNBC TV18 Market

Comentarios


bottom of page